



Guideline for the management of severe local anaesthetic toxicity on the birthing centre

Author/Owner	Lead obstetric anaesthetic consultant	
Equality Impact Assessment	N/A if clinical guideline or procedure	
Version	2	
Status	Approved	
Publication date	03/06/2021	
Review date	24/03/2024	
Approval recommended by	Maternity guideline group	Date: 04/01/2021
	Women's Business and Governance Meeting	Date: 22/01/2021
Approved by	CBU 3 Overarching Governance Meeting	Date: 24/03/2021
Distribution	Barnsley Hospital NHS Foundation Trust – intranet Please note that the intranet version of this document is the only version that is maintained. Any printed copies must therefore be viewed as “uncontrolled” and as such, may not necessarily contain the latest updates and amendments	



Table of Contents

	Section heading	Page
1.0	Introduction	3
2.0	Objective	3
3.0	Scope	3
4.0	Main body of the document	3
5.0	Roles and responsibilities	5
	5.1 Midwives	5
	5.2 Obstetricians	5
	5.3 Anaesthetists	5
6.0	Associated documents and references	5
7.0	Training and resources	5
8.0	Monitoring and audit	5
9.0	Equality, diversity and inclusion	6
	9.1 Recording and monitoring of equality, diversity and inclusion	6
Appendix 1	Equality impact assessment – required for policy only	7
Appendix 2	Glossary of terms	7
Appendix 3	Document history/version control – must be the last appendix	7
	Approval form	8



1.0 Introduction

Local Anaesthetic systemic toxicity (LAST) is a potentially fatal complication caused by a high circulating plasma concentration of local anaesthetic generally occurring as a result of accidental intravenous injection or delayed absorption from the anaesthetic depot at the injection site.

Pregnancy increases the risk of LAST due to the hormonal and circulatory physiological changes which occur.

LAST has been recognised as an important potential cause of maternal mortality which is compounded by the increase in complex cases due to increased maternal age, obesity, and co-morbidities.

Pregnant women in cardiac arrest may have a poorer survival rate and resuscitation is complicated by the physiological changes of pregnancy. Therefore, it is important that perimortem LSCS is considered in a pregnant woman who arrests as a result of LAST.

2.0 Objective

To ensure the timely recognition and management of severe local anaesthetic toxicity following regional anaesthesia.

3.0 Scope

This guideline applies to all medical and midwifery staff working on the maternity unit.

4.0 Main body of the document

Local anaesthetic systemic toxicity (LAST) must be considered when women who are receiving epidural analgesia or have had local anaesthetic infiltration for any reason, show any of the signs of toxicity listed below. Remember local anaesthetic (LA) toxicity may occur sometime after the initial injection especially if an infusion is running.

4.1 Signs of severe toxicity:

- Peri-oral tingling may be an early sign of LA toxicity
- Sudden alteration of mental state
- Severe agitation
- Sudden loss of consciousness, with or without tonic-clonic convulsions
- Cardiovascular collapse:
 - sinus bradycardia
 - conduction blocks
 - hypotension
 - ventricular tachyarrhythmias
 - asystole

4.2 Immediate management:

- Stop injecting the LA / switch off epidural infusion
- **Call for help:**
 - **Inform shift leader and put out a Code Blue call**
 - The cardiac arrest team will also be required if the woman has or is in danger of having a cardiac arrest.
 - The Neonatal resuscitation team will be required if a peri-



mortem caesarean section is required

- Fetch the cardiac arrest trolley and the intralipid – intralipid is stored in the obstetric theatre in the emergency drug drawer and also in the cupboard used to store the epidural infusion bags
- Give 100% oxygen and ensure adequate lung ventilation – maintain the airway and ensure early intubation in event of cardiac arrest (hyperventilation may help by increasing pH in the presence of metabolic acidosis)
- Confirm or establish intravenous access

4.3 If circulatory arrest:

- Start continuous CPR according to ALS protocol
- **Give** intralipid – see below for regime
 - **PREPARE FOR PERI-MORTEM CAESAREAN SECTION AFTER 4 MINUTES OF CPR – BABY SHOULD BE DELIVERED BY 5 MINS**

4.4 If no circulatory arrest

- Use conventional therapies to treat hypotension, bradycardia or tachyarrhythmias.
- **Consider** intralipid therapy – as regime below
- Monitor the baby for signs of fetal distress associated with the maternal compromise.
- Control seizures with small incremental dose of benzodiazepine, thiopentone or propofol.

4.5 Intralipid treatment regime

Intralipid treatment regime

- Give an intravenous bolus injection of Intralipid® 20% 1.5 ml.kg⁻¹ over 1 min (approx. 100ml of lipid emulsion in 70kg adult)
- Continue CPR
- Start an intravenous infusion of Intralipid® 20% at 15 ml.kg⁻¹hr⁻¹ (17.5ml/min in 70kg adult)
- **If no cardiac output at 5 mins perimortem Caesarean section must be performed**
- Repeat the bolus injection twice at 5 min intervals if an adequate circulation has not been restored or an adequate circulation deteriorates
- After the infusion has been running for 5 mins, increase the rate to 30ml.kg⁻¹hr⁻¹ if an adequate circulation has not been restored
- Continue infusion until a stable and adequate circulation has been restored or maximum dose of lipid emulsion has been given.
- A maximum of three boluses can be given (including the initial bolus)
- Do not exceed a maximum cumulative dose of 12 ml.kg⁻¹ (840ml in 70kg adult)



4.6 Remember:

- Continue CPR throughout treatment with lipid emulsion
- Prolonged resuscitation may be necessary
- Recovery from LA-induced cardiac arrest may take >1 hour
- The woman will need monitoring on the Critical Care Unit (CCU) post recovery
- Arrange safe transfer with appropriate equipment and suitable staff following liaison with staff on CCU

5.0 Roles and responsibilities

5.1 Midwives

To monitor women with regional anaesthesia for adverse effects.

To work as part of a multi-disciplinary team to manage the potentially life threatening occurrence of local anaesthetic toxicity.

5.2 Obstetricians

To work as part of a multi-disciplinary team to manage the potentially life threatening occurrence of local anaesthetic toxicity.

5.3 Anaesthetists

To co-ordinate and manage the potentially life threatening occurrence of local anaesthetic toxicity.

6.0 Associated documents and references

Quick reference handbook (2018) The Association of Anaesthetists of Great Britain and Ireland

The Association of Anaesthetists of Great Britain & Ireland AAGBI safety Guideline, Management of Severe Local Anaesthetic Toxicity (2010)

Sarah Bern, Guy Weinberg (2011). Local anaesthetic toxicity and lipid resuscitation in pregnancy [online]<http://www.ncbi.nlm.nih.gov/pubmed/2149132> accessed 17/04/2013

7.0 Training and resources

Training will be delivered as outlines in the Maternity Training Needs Analysis. This is updated on an annual basis.

8.0 Monitoring and audit

Any adverse incidents relating to the guideline for the management of severe local anaesthetic toxicity on the birthing centre will be monitored via the incident reporting system. Any problems will be actioned via the case review and root cause analysis action plans. The action plans are monitored by the risk midwife to ensure that improvements in care are made. The trends and any root cause analysis are discussed at the monthly risk meetings to ensure that appropriate action has been taken to maintain safety.

The guideline for the management of severe local anaesthetic toxicity on the birthing centre will be audited in line with the annual audit programme, as agreed by the CBU. The audit



action plan will be reviewed at the monthly risk management meetings on a quarterly basis and monitored by the risk midwife to ensure that improvements in care are made.

9.0 Equality and Diversity

The Trust is committed to an environment that promotes equality and embraces diversity in its performance as an employer and service provider. It will adhere to legal and performance requirements and will mainstream equality, diversity and inclusion principles through its policies, procedures and processes. This guideline should be implemented with due regard to this commitment.

To ensure that the implementation of this guideline does not have an adverse impact in response to the requirements of the Equality Act 2010 this policy has been screened for relevance during the policy development process and a full equality impact assessment is conducted where necessary prior to consultation. The Trust will take remedial action when necessary to address any unexpected or unwarranted disparities and monitor practice to ensure that this policy is fairly implemented.

This guideline can be made available in alternative formats on request including large print, Braille, moon, audio, and different languages. To arrange this please refer to the Trust translation and interpretation policy in the first instance.

The Trust will endeavor to make reasonable adjustments to accommodate any employee/patient with particular equality, diversity and inclusion requirements in implementing this guideline. This may include accessibility of meeting/appointment venues, providing translation, arranging an interpreter to attend appointments/meetings, extending policy timeframes to enable translation to be undertaken, or assistance with formulating any written statements.

9.1 Recording and Monitoring of Equality & Diversity

The Trust understands the business case for equality, diversity and inclusion and will make sure that this is translated into practice. Accordingly, all guidelines will be monitored to ensure their effectiveness.

Monitoring information will be collated, analysed and published on an annual basis as part of Equality Delivery System. The monitoring will cover the nine protected characteristics and will meet statutory employment duties under the Equality Act 2010. Where adverse impact is identified through the monitoring process the Trust will investigate and take corrective action to mitigate and prevent any negative impact.



Appendix 1
Equality Impact Assessment – required for policy only

Appendix 2
Glossary of terms

- ALS – Advanced life support
- CCU – Critical Care Unit
- CPR – Cardiopulmonary resuscitation
- LA – Local Anaesthetic
- LAST – Local Anaesthetic Systemic Toxicity
- NRLS – National reporting and learning system
- SHO – Senior house officer

Appendix 3

Maintain a record of the document history, reviews and key changes made (including versions and dates)

Version	Date	Comments	Author
1	06/07/2010		
2	06/03/2013		

Review Process Prior to Ratification:

Name of Group/Department/Committee	Date
Reviewed by Maternity Guideline Group	04/01/2021
Reviewed at Women’s Business and Governance meeting	22/01/2021
Approved by CBU 3 Overarching Governance Meeting	24/03/2021
Approved at Trust Clinical Guidelines Group	13/05/2021
Approved at Medicines Management Committee (if document relates to medicines)	N/A


Approval Form

Please complete the following information and attach to your document when submitting a policy, clinical guideline or procedure for approval.

Document type (policy, clinical guideline or procedure)	Guideline
Document title	Management of severe local anaesthetic toxicity on the birthing centre
Document author (Job title and team)	Dr Ellwood/G Dunning
New or reviewed document	Reviewed
List staff groups/departments consulted with during document development	Senior midwives, obstetric consultants, lead obstetric anaesthetist
Approval recommended by (meeting and dates):	Reviewed by Maternity Guideline Group Reviewed at Women's Business and Governance meeting Approved by CBU 3 Overarching Governance Meeting Approved at Trust Clinical Guidelines Group
Date of next review (maximum 3 years)	24/03/2021
Key words for search criteria on intranet (max 10 words)	Local anaesthetic toxicity
Key messages for staff (consider changes from previous versions and any impact on patient safety)	
I confirm that this is the <u>FINAL</u> version of this document	Name: Charlotte Cole Designation: Practice Educator Midwife

FOR COMPLETION BY THE CLINICAL GOVERNANCE TEAM

Approved by (group/committee): CBU 3 Overarching Governance & Trust Clinical Guidelines Group Date approved: 13/05/2021 Date Clinical Governance Administrator informed of approval:13/05/2021 Date uploaded to Trust Approved Documents page:03/06/2021
